Scott Gottlieb’s sudden resignation will give biotech a panic attack
The news that Scott Gottlieb will step down is likely to leave pharma executive and health care investors nervous at best and frightened at worst.
Scott Gottlieb, the highly effective and well-liked commissioner of the Food and Drug Administration, announced Tuesday that he would quit, leaving himself only a month to wrap up his plans like spurring the development of new drugs and regulating electronic cigarettes.
That news is likely to leave biotech and pharma executives, who largely adored Gottlieb, nervous at best and frightened at worst. Likewise, health care investors. That’s not because they thought Gottlieb was necessarily so great. It’s because the libertarian figures whose names were
